Related Experiment Video
Updated: Aug 5, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
THE ROLE OF BIOCHEMICAL MARKERS AND PATIENT-REPORTED OUTCOMES IN PREDICTING COMPOSITE ONE-YEAR ENDPOINT IN ST-SEGMENT
Iryna R Vyshnevska1, Olga V Petyunina1, Mykola P Kopytsya1
1GI "L.T. MALAYA THERAPY NATIONAL INSTITUTE OF THE NAMS OF UKRAINE", KHARKIV, UKRAINE.
Insights
Matrix metalloproteinase-9 (MMP-9) levels and EQ-5D scores predict major adverse cardiovascular events in STEMI patients one year after primary PCI. These markers aid in assessing long-term outcomes for ST-elevation myocardial infarction survivors.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- ST-elevation myocardial infarction (STEMI) is a critical condition requiring timely intervention.
- Primary percutaneous coronary intervention (PCI) is the standard treatment for STEMI.
- Predicting long-term outcomes after STEMI is crucial for patient management.
Purpose of the Study:
- To evaluate the predictive role of clinical and biochemical markers for one-year outcomes in STEMI patients post-primary PCI.
- To assess the utility of Matrix metalloproteinase-9 (MMP-9) and the EQ-5D questionnaire in outcome prediction.
Main Methods:
- A cohort of 165 STEMI patients admitted within 12 hours of symptom onset were included.
- Patients underwent primary PCI followed by standard care.
- Blood samples for MMP-9 and cTnI were collected on admission; clinical follow-up was conducted at six months and one year.
Main Results:
- The one-year composite endpoint occurred in 9% of patients.
- ROC analysis indicated MMP-9 (AUC=0.711) and EQ-5D (AUC=0.73) are significant predictors.
- Logistic regression showed EQ-5D (OR=0.89) and MMP-9 (OR=1.0151) were statistically associated with the composite endpoint.
Conclusions:
- MMP-9 levels >194 ng/ml and EQ-5D scores <55 predict major adverse cardiovascular events within one year post-primary PCI in STEMI patients.
- These markers can help identify patients at higher risk for cardiovascular mortality and heart failure.
- Further research is warranted to validate these findings.
Objective:
Aim of our study was to determine the role of the clinical and biochemical markers in predicting the outcomes at one year in patients with STEMI who have undergone primary PCI.
Patients And Methods:
Materials and methods: The study included 165 patients admitted with STEMI within 12 hours of the onset of symptoms be¬tween January 2020 and August 2021. All patients underwent primary PCI according to the guidelines, followed by standard examination and treatment at the hospital. Blood samples for biomarker analysis (MMP-9, cTnI) and other routine tests were taken on admission. At six months after the event, all patients underwent clinical follow-up. Patients were contacted either by phone, through family members or their physicians 1 year after the event.
Results:
Results: The composite endpoint reached 9% of patients at one-year follow-up. ROC analysis of MMP-9 with the one-year com¬posite endpoint showed an AUC=0.711, with 91.7% sensitivity, and 47.4% specificity, 95% CI - 0.604 to 0.802, p=0.0037. ROC analysis of EQ-5D questionnaire with the one-year composite endpoint showed AUC = 0.73, the 95% CI - 0.624 to 0.820, p< 0.0195, with sensitivity 54.5% and specificity 94.7%. A logistic regression model showed a statistical association with the com¬posite endpoint at one year after STEMI in both EQ-5D (OR=0.89, 95% CI: 0.8313- 0.9725, p=0.0079) and MMP-9 (OR=1.0151, 95% CI:1.0001-1.0304, p=0.0481).
Conclusion:
Conclusions: The level of MMP-9 more than 194 ng/ml and <55 points in EQ-5D predicts major adverse cardiovascular events, in¬cluding cardiovascular mortality and progressive heart failure, as well as other elements of composite endpoints, during a 1-year follow-up in patients with STEMI after primary PCI. Future studies are needed to clarify this result.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests